Company profile
Ginkgo Bioworks Holdings, Inc.
NYSE: DNA · Healthcare · Biotechnology
#302 of 1,418 Healthcare companies by revenue26th-percentile growth
EA Score
44DFH 43DQ 51GM 26SS 59
v0.1 · 65/100 weight · provisional
↑ workforce scale, market scale · ↓ listing tenure, 3-yr revenue growth
Methodology →Revenue TTM
$141.3M
Rev growth YoY (TTM)
-40.5%
Net income (FY)
-$312.8M
Employees
485
as of 2026-08-11
Market cap
$499.7M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$170.2M$170.2M2025
Net income-$312.8M-$312.8M2025
Operating income-$315.3M-$315.3M2025
Total assets$1.1B$1.1B2025
Liabilities$611.1M$611.1M2025
Equity$508.6M$508.6M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Service100%
By geography
Not disclosed.
The read
What is Ginkgo Bioworks Holdings, Inc.’s revenue?
Ginkgo Bioworks Holdings, Inc. booked $170.2M in FY2025 revenue, contracting 25% year over year — slower than 74% of Healthcare companies we track, at a -183.8% net margin.
Peers · Healthcare
Medicine Man Technologies, Inc.——Syndax Pharmaceuticals, Inc.52DREGENXBIO Inc.54DMaze Therapeutics, Inc.49DPacific Biosciences of California, Inc.55CMariMed Inc.66BNeighbors
Suffolk →Key facts
CEOJason Kelly
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, MA
ExchangeNYSE: DNA
Employees485
IPO date2021-04-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.